Cargando…

Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis

BACKGROUND: Non-ergot dopamine agonists (NEDAs) have been used as monotherapy or as an adjunctive therapy to levodopa for many years. Novel long-acting formulations of NEDAs including pramipexole extended-release (ER), ropinirole prolonged-release (PR), and rotigotine transdermal patch have been dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiang-Ting, Zhang, Qian, Chen, Fei-Fei, Wen, Si-Yuan, Zhou, Chang-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312085/ https://www.ncbi.nlm.nih.gov/pubmed/37396766 http://dx.doi.org/10.3389/fneur.2023.1183823

Ejemplares similares

Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022)

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease
por: Jing, Xiao-Zhong, et al.
Publicado: (2023)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Non-ergot dopamine agonists and heart failure
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials
por: Wu, Chunxiao, et al.
Publicado: (2022)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
por: Clausen, Marianne F., et al.
Publicado: (2021)

Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists
por: Ikeda, Ken, et al.
Publicado: (2016)

Delusional Infestation Secondary to the Dopamine Agonist Ropirinole in a Patient With Parkinson's Disease: A Case Report With an Outline of the Biology of Psychosis
por: Kesserwani, Hassan
Publicado: (2021)

Pathogenic free-living amoebic encephalitis from 48 cases in China: A systematic review
por: Chen, Xiang-Ting, et al.
Publicado: (2023)

Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson’s Disease Patients: A Meta-Analysis of Randomized Controlled Trials
por: De Vecchis, Renato, et al.
Publicado: (2016)

Evaluation of the effect of non-ergot dopamine agonists on left ventricular systolic function with speckle tracking echocardiography
por: Pamukcu, Hilal Erken, et al.
Publicado: (2018)

Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease
por: O'Gorman Tuura, Ruth L., et al.
Publicado: (2018)

Efficacy and safety of botulinum toxin for treating motor dysfunction in patients with Parkinson’s disease: a systematic review and meta-analysis
por: Yang, Yuqi, et al.
Publicado: (2023)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Effect of LRRK2 G2385R Variant on Subthalamic Deep Brain Stimulation Efficacy in Parkinson's Disease in a Han Chinese Population
por: Chen, Si, et al.
Publicado: (2019)

SLC6A3 Polymorphism Predisposes to Dopamine Overdose in Parkinson's Disease
por: Robertson, Brian D., et al.
Publicado: (2018)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Comparative Efficacy and Safety of Dopamine Agonists in Advanced Parkinson's Disease With Motor Fluctuations: A Systematic Review and Network Meta-Analysis of Double-Blind Randomized Controlled Trials
por: Ruan, Xinglin, et al.
Publicado: (2021)

Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease
por: Zhang, Li-Min, et al.
Publicado: (2015)

Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease
por: Black, Kevin J., et al.
Publicado: (2020)

Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study
por: Erro, Roberto, et al.
Publicado: (2021)

Case report: Dopamine Dysregulation Syndrome, mania, and compulsive buying in a patient with Parkinson's disease
por: Silva, Carlos, et al.
Publicado: (2023)

Ergot
por: Smith, T. Curtis
Publicado: (1875)

The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial(†)
por: Busso, Cristiano, et al.
Publicado: (2010)

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
por: Pagano, Gennaro, et al.
Publicado: (2021)

High national rates of high-dose dopamine agonist prescribing for restless legs syndrome
por: Winkelman, John W
Publicado: (2021)

Comparative Efficacy and Safety of 11 Drugs as Therapies for Adults With Neuropathic Pain After Spinal Cord Injury: A Bayesian Network Analysis Based on 20 Randomized Controlled Trials
por: Ling, Hai-Qian, et al.
Publicado: (2022)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials
por: Wang, Qinghui, et al.
Publicado: (2023)

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
por: Ch, Saritha, et al.
Publicado: (2022)

Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients
por: Yuan, Jiawen, et al.
Publicado: (2022)

Anti-Dopamine Receptor 2 Antibody-Positive Encephalitis in Adolescent
por: Dai, Xuejiao, et al.
Publicado: (2020)

Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review
por: Yan, Junqiang, et al.
Publicado: (2021)

Multi-session transcutaneous auricular vagus nerve stimulation for Parkinson's disease: evaluating feasibility, safety, and preliminary efficacy
por: Lench, Daniel H., et al.
Publicado: (2023)

Ergot of Rye
Publicado: (1831)

Ergot in Menorrhagia
Publicado: (1857)

Ergot of Wheat
Publicado: (1857)

Ergot in Dysentery
Publicado: (1874)

Ergot-Poisoning
por: Keating, John M.
Publicado: (1880)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ks05dsb3ainoj8oo2m99vabvq9